title: rAAt (dermatological) Arriva/ProMetic.
abstract: Arriva Pharmaceuticals Inc and ProMetic Life Sciences Inc are developing a gel formulation of recombinant alpha1-antitrypsin (rAAT). The therapy, as a topical formulation, is in phase II clinical trials for the potential treatment of atopic dermatitis and severe dermatological disorders. rAAT is also under preclinical investigation for the potential treatment of other inflammatory skin conditions, including psoriasis, as well as for otitis media.
authors.affiliation: Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com
authors.forename: William M
authors.initials: WM
authors.lastname: Brown
mesh_terms: D000287:Administration, Topical; D017322:Clinical Trials, Phase II as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004345:Drug Industry; D006801:Humans; D013329:Structure-Activity Relationship; D000515:alpha 1-Antitrypsin / Q000096:biosynthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D000515:alpha 1-Antitrypsin